<DOC>
	<DOCNO>NCT01107496</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel group , safety tolerability study adult ADHD . The target subject healthy male female adult age 18 64 year , inclusive , diagnosis ADHD . A total fifty subject enrol approximately 5 site US . Subjects randomize ( 1:1 ) one two treatment group , SPN-812V placebo .</brief_summary>
	<brief_title>A Phase I/IIa , Randomized , Double-Blind , Multicenter , Placebo-Controlled , Parallel-Group Study Safety , Efficacy SPN-812V Adults With Attention Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<criteria>Inclusion criterion : 1 . Able provide inform consent prior study procedure conduct . 2 . Capable willing comply study procedure . 3 . Male female age 18 64 , inclusive . 4 . Subjects current diagnosis ADHD confirm Conners ' Adult ADHD Diagnostic Interview DSMIV ( CAADID ) 5 . Clinical Global Impression Severity ( CGIS ) score 4 high . 6 . On treatment ADHD willing withdrawn ongoing treatment washout least 10 day . 7 . Body Mass Index ( BMI ) 18.0 34.0 inclusive . 8 . Subject must general good health determine medical history , ECG , analysis , judgment Investigator , would confirm Subject 's good health . 9 . Females childbearing potential ( FOCP ) , sexually active , agree use acceptable form contraception ( include oral , transdermal , implanted contraceptive ; intrauterine device ; female condom spermicide ; diaphragm spermicide ; cervical cap ; abstinence ; use condom spermicide sexual partner sterile [ least 6 month prior SM administration ] sexual partner ) least 14 day prior start study drug administration , throughout study , 30 day follow last dose SM . 10 . Postmenopausal females amenorrhea least 2 year females permanently sterilize ( e.g. , tubal occlusion , hysterectomy , bilateral salpingectomy ) . Exclusion Criteria 1 . Current past history psychotic disorder major depressive disorder psychotic feature . 2 . Presence another primary DSMIVTR disorder . 3 . Suicidality , define either active suicidal plan/intent active suicidal thought , 6 month Screening Visit 1 lifetime suicide attempt . ( The ColumbiaSuicide Severity Rating Scales [ CSSRS ] administer visit . ) 4 . Substance alcohol abuse/dependence within previous 6 month , positive urine drug screen screen baseline prior first dose study medication ( SM ) . 5 . Any known suspected significant medical psychiatric illness , judgment Investigator , may impair interpretation study result constitute significant safety concern context clinical trial 6 . ECG abnormality ( clinically significant accord Investigator 's opinion ) vital sign abnormality ( systolic blood pressure [ SBP ] &lt; 90 &gt; 140 millimeter mercury [ mmHg ] , diastolic blood pressure [ DBP ] &lt; 40 &gt; 90mmHg , heart rate [ HR ] &lt; 40 &gt; 100 beat per minute [ BPM ] ) screening . 7 . Clinically significant laboratory abnormality ; include presence potential hepatic function impairment show , limited alanine aminotransferase ( ALT/SGPT ) value &gt; 2 time upper limit normal ( ULN ) , aspartate aminotransferase ( AST/SGOT ) &gt; 2 time ULN , gammaglutamyl transpeptidase ( GGT ) &gt; 3 time ULN , total bilirubin &gt; 1.5 ULN . 8 . Medications , include health food supplement judge Investigator likely central nervous system activity ( example , St John 's Wort , gingko leaf , melatonin ) , permit study . If subject take medication prior study entry , must 7 day washout period prior first dose SM . 9 . Lifetime history tic disorder , Tourette 's Disease , organic brain disorder ; family history Tourette 's Disease . 10 . Current lifetime history hyperthyroidism unless treat stable least 6 month . 11 . Participation plan begin behavioral therapy study . 12 . Subject prior history allergy significant adverse reaction ( include rash ) study medication , product component . 13 . Females pregnant lactate unwilling use acceptable form contraception throughout study . 14 . Difficulty swallow whole capsule . 15 . History seizure risk factor seizure ( e.g. , head trauma ) , include febrile seizure . 16 . Use investigational drug participation investigational study within 30 day prior first dose SM . 17 . Any reason , opinion Investigator , would prevent subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>